J&J Expects Financial Ripple Effect From McNeil OTC Recall
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson expects the recall of pediatric liquid OTCs, including Tylenol and Motrin products, to diminish the firm's overall margins in addition to temporarily halting sales of some of its highest margin consumer products